Merrill S. Kies

Active 1987–2024

68
Papers
19,491
Citations
66
h-index
68
i10-index

Citations

Citations per year for Merrill S. Kies1989: 1 citations1990: 1 citations1992: 7 citations1993: 7 citations1994: 1 citations1995: 6 citations1996: 5 citations1997: 11 citations1998: 6 citations1999: 10 citations2000: 10 citations2001: 25 citations2002: 24 citations2003: 33 citations2004: 63 citations2005: 59 citations2006: 120 citations2007: 149 citations2008: 161 citations2009: 194 citations2010: 169 citations2011: 182 citations2012: 166 citations2013: 183 citations2014: 173 citations2015: 144 citations2016: 148 citations2017: 152 citations2018: 95 citations2019: 491 citations2020: 523 citations2021: 434 citations2022: 306 citations2023: 228 citations2024: 290 citations2025: 125 citations2026: 4 citations1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,112 citing papers, 33.5% of this breakdownChina: 415 citing papers, 6.6% of this breakdownUnited Kingdom: 345 citing papers, 5.5% of this breakdownItaly: 300 citing papers, 4.8% of this breakdownGermany: 295 citing papers, 4.7% of this breakdownFrance: 280 citing papers, 4.4% of this breakdownNetherlands: 262 citing papers, 4.2% of this breakdownCanada: 258 citing papers, 4.1% of this breakdownJapan: 204 citing papers, 3.2% of this breakdownAustralia: 160 citing papers, 2.5% of this breakdownSpain: 152 citing papers, 2.4% of this breakdownBelgium: 126 citing papers, 2% of this breakdown
0%33.5%Other 22.1%

Fields

  • Medicine75.2%
  • Biochemistry, Genetics and Molecular Biology14.6%
  • Immunology and Microbiology3%
  • Health Professions1.7%
  • Mathematics1.2%
  • Physics and Astronomy1%
  • Other3.3%

Topics

  • Head and Neck Cancer Studies11.5%
  • Lung Cancer Treatments and Mutations4.4%
  • Head and Neck Surgical Oncology3.1%
  • Oral health in cancer treatment3.1%
  • Salivary Gland Tumors Diagnosis and Treatment3%
  • Lung Cancer Research Studies2.7%
  • Other72.2%

Coauthors

All papers

Open in search
  1. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 5,106

  2. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 471

  3. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2012 cited by 391

  4. The BATTLE Trial: Personalizing Therapy for Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2011 cited by 893

  5. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module

    Authors: , , , , , , , , , , , - Head & Neck 2007 cited by 314

  6. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis

    Authors: , , , , , , , , , , , , , , , , , , - Radiotherapy and Oncology 2016 cited by 231

  7. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial

    Authors: , , , , , , , - Journal of the American Academy of Dermatology 2017 cited by 121

  8. Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations

    Authors: , , , , , , , , , , - Clinical Cancer Research 2015 cited by 201

  9. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial

    Authors: , , , , , - Cancer 2018 cited by 113

  10. Phase II study of gefitinib in patients with advanced salivary gland cancers

    Authors: , , , , , , , , - Head & Neck 2014 cited by 113

  11. A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , - New England Journal of Medicine 1992 cited by 1,333

  12. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study

    Authors: , , , , , , , , , , , , , , , , , - JCO Precision Oncology 2017 cited by 161

  13. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2015 cited by 159

  14. Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911

    Authors: , , , , , , , - Journal of Clinical Oncology 2007 cited by 362

  15. Head and Neck Cancers, Version 2.2014

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2014 cited by 281

  16. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2014 cited by 218

  17. Multifield Optimization Intensity Modulated Proton Therapy for Head and Neck Tumors: A Translation to Practice

    Authors: , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2014 cited by 151

  18. Outcomes for olfactory neuroblastoma treated with induction chemotherapy

    Authors: , , , , , , , , , , , - Head & Neck 2017 cited by 87

  19. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study

    Authors: , , , , , , , , , , , , , , , , , , , , - npj Precision Oncology 2021 cited by 27

  20. Beam Path Toxicities to Non-Target Structures During Intensity-Modulated Radiation Therapy for Head and Neck Cancer

    Authors: , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2008 cited by 200

  21. Head and Neck Cancers, Version 1.2015

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2015 cited by 269

  22. Quality of Life in Head and Neck Cancer Patients After Treatment With High-Dose Radiotherapy Alone or in Combination With Cetuximab

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 246

  23. Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group

    Authors: , , , , , , - Head & Neck 2006 cited by 178

  24. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma

    Authors: , , , , , , , , , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2016 cited by 128